|
1）Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988; 12: 56-62
|
|
|
|
2）Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992; 326: 310-8
|
|
|
|
|
|
3）Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657-71
|
|
|
|
|
|
4）Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999; 100: 230-5
|
|
|
|
|
|
5）Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767-72
|
|
|
|
|
|
6）Ridker PM, Rifai N, Clearfield M, et al; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344: 1959-65
|
|
|
|
|
|
7）Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340: 115-26
|
|
|
|
|
|
8）Tahara N, Imaizumi T, Virmani R, et al. Clinical feasibility of molecular imaging of plaque inflammation in atherosclerosis. J Nucl Med. 2009; 50: 331-4
|
|
|
|
|
|
9）Barger AC, Beeuwkes R, Lainey LL, et al. Hypothesis: vasa vasorum and neovas- cularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984; 310: 175–7
|
|
|
|
|
|
10）Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005; 25: 2054-61
|
|
|
|
|
|
11）Narula J, Strauss HW. The popcorn plaques. Nat Med. 2007; 13: 532-4
|
|
|
|
|
|
12）Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994; 90: 775-8
|
|
|
|
|
|
13）van der Wal AC, Becker AE, Koch KT, et al. Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques. Heart. 1996; 76: 312-6
|
|
|
|
|
|
14）Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992; 33: 1972-80
|
|
|
|
|
|
15）Kubota R, Kubota K, Yamada S, et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994; 35: 104-12
|
|
|
|
|
|
16）Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708-11
|
|
|
|
|
|
17）Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006; 48: 1818-24
|
|
|
|
|
|
18）Rudd JH, Myers KS, Bansilal S, et al. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50: 892-6
|
|
|
|
|
|
19）Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography J Am Coll Cardiol. 2006; 48: 1825-31
|
|
|
|
|
|
20）Mizoguchi M, Tahara N, Tahara A, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging. 2011; 4: 1110-8
|
|
|
|
|
|
21）Suzuki K, Kono T. Evidence that insulin causes translocation of glucose transport activity to the plasma membrane from an intracellular storage site. Proc Natl Acad Sci U S A. 1980; 77: 2542-5
|
|
|
|
|
|
22）Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010; 3: 388-97
|
|
|
|
|
|
23）Rudd JH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010; 55: 2527-35
|
|
|
|
|
|
24）Tahara N, Tahara A, Narula J, et al. Statin therapy resolves coronary artery inflammation. JACC Cardiovasc Imaging. 2013; 6: 1119-20
|
|
|
|
|
|
25）Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-78
|
|
|
|
|
|
26）Suda K, Tahara N, Kudo Y, et al. Persistent coronary arterial inflammation in a patient long after the onset of Kawasaki disease. Int J Cardiol. 2012; 154: 193-4
|
|
|
|
|
|
27）Suda K, Tahara N, Honda A, et al. Statin reduces persistent coronary arterial inflammation evaluated by serial 18fluorodeoxyglucose positron emission tomography imaging long after Kawasaki disease. Int J Cardiol. 2015; 179: 61-2
|
|
|
|
|
|
28）Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279-89
|
|
|
|
|
|
29）Erdmann E, Dormandy, JA, Charbonnel B, et al; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007; 49: 1772-80
|
|
|
|
|
|
30）Nitta Y, Tahara N, Tahara A, et al. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging. JACC Cardiovasc Imaging. 2013; 6: 1172-82
|
|
|
|
|
|
31）Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004; 291: 210-5
|
|
|
|
|
|
32）Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008; 358: 1336-45
|
|
|
|
|
|
33）Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol. 2007; 50: 319-26
|
|
|
|
|
|
34）Shioi A, Taniwaki H, Jono S, et al. Monckeberg’s medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis. 2001; 38: S47–9
|
|
|
|
|
|
35）Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006; 26: 1423-30
|
|
|
|
|
|
36）Tyson KL, Reynolds JL, McNair R, et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arteriscler Thromb Vasc Biol. 2003; 23: 489-94
|
|
|
|
|
|
37）Atkinson J. Age-related medial elastocalcinosis inarteries: mechanisms, animal models, and physiological consequences. J Appl Physiol. 2008; 105: 1643-51
|
|
|
|
|
|
38）Aikawa E, Nahrendorf M, Figueiredo JL, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007; 116: 2841-50
|
|
|
|
|
|
39）New SE, Goettsch C, Aikawa M, et al. Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ Res. 2013; 113: 72-7
|
|
|
|
|
|
40）Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014; 383: 705-13
|
|
|
|
|
|
41）Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012; 59: 1539-48
|
|
|
|
|
|
42）Derlin T, Tóth Z, Papp L, et al. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med. 2011; 52: 1020-7
|
|
|
|
|